Day One

Below is a summary of the session timetable for Day One. Greater detail for each session, including speakers and presentation titles, is given further down the page.

Biomedical meeting Clinical meeting
Session 1: Joint Opening Session
Session 2A: Cell Biology and Pathology Session 2B: Autonomy and Quality of Life
Session 3A: RNA Binding and Transport Session 3B: Technology and ALS
Session 4A: RNA and Stress Response Session 4B: Clinical Trials
Poster session A

 

Joint SessionBiomedical meetingClinical meeting
Session 1: 08.45 - 10.20
08.45 - 09.00 Welcome to the Symposium S Light, Chief Executive of MND Association (UK) and K Talbot (UK)
Welcome from Host Association
09.00 - 09.45 ALS/MND: Defining the disease J Rosenfeld (USA)
09.45 - 10.00 International Alliance Humanitarian Award and Forbes Norris Award
10.00 - 10.20 Instituto Paulo Gontijo (IPG) Award and winner's research presentation
 

Session 2A: 11.00 - 12.40
CELL BIOLOGY AND TRANSPORT
11.00 - 11.30 The ‘lateral sclerosis’ half of ALS: Corticospinal (‘upper’) motor neurons from Charcot to their molecular development, diversity, circuitry, and growth cones J Macklis (USA)
11.30 - 11.50 Synapse dysfunction of layer V pyramidal neurons precedes neurodegeneration in a mouse model of TDP-43 proteinopathies E Handley (Australia)
11.50 - 12.10 Mechanisms of FUS mediated ALS: Insights from mouse genetics L Dupuis (France)
12.10 - 12.25 Functional analysis of the ALS-associated miR-1825 A Helferich (Germany)
12.25 - 12.40 Identification of target mRNA transported to axons by TDP-43 S Nagano (Japan)

Session 3A: 14.00 - 15.30
RNA BINDING AND TRANSPORT
14.00 – 14.30 RNA-binding proteins and nucleocytoplasmic transport defects in ALS L Van Den Bosch (Belgium)
14.30 – 14.50 The nuclear pore complex is compromised is sALS and ALS/FTD J Grima (USA)
14.50 – 15.10 Safety and efficacy of SRSF1-dependent nuclear export inhibition of C9ORF72 repeat-transcripts: Moving towards therapies L Castelli (UK)
15.10 – 15.30 Phase separation of FUS is suppressed by the nuclear import receptor Transportin and FUS arginine methylation D Dormann (Germany)

Session 4A: 16.00 - 17.30
RNA AND STRESS RESPONSE
16.00 – 16.30 Neuroprotective effects of angiogenin-induced tRNA cleavage P Anderson (USA)
16.30 – 16.50 Mild chronic stresses sensitise neurons to the acute strong stress by reducing their capacity to maintain stress granule assembly V Buchman (UK)
16.50 – 17.10 Dynamics and nature of inclusions of TDP-43 and its isoforms A Weichert (Canada)
17.10 – 17.30 Role of RNA G-quadruplex structures in the molecular pathology of C9orf72-ALS J Gallo (UK)


Session 2B: 11.00 - 12.30
AUTONOMY AND QUALITY OF LIFE
11.00 – 11.30 Communication in serious illness: An evidence-based approach J Tulsky (USA)
11.30 – 11.50 Health status perspective in ALS S Pinto (Portugal)
11.50 – 12.10 ALS patients with locked-in syndrome: Quality of life, depression and medical decision making D Lulé (Germany)
12.10 – 12.30 A systematic review of decision making among patients and their family in ALS care G Foley (Ireland)

Session 3B: 14.00 - 15.30
TECHNOLOGY AND ALS
14.00 – 14.30 Enhancing neurological care through telemedicine R Dorsey (USA)
14.30 – 15.00 Will telehealth revolutionize clinical care for ALS patients? S Perrin (USA)
15.00 – 15.30 BrainGate: Toward restoring communication and mobility L Hochberg (USA)

Session 4B: 16.00 - 17.45
CLINICAL TRIALS
16.00 – 16.20 Masitinib as an add-on therapy to riluzole is safe and effective in the treatment of ALS J S Mora (Spain)
16.20 – 16.40 VITALITY-ALS: Results of a phase 3 trial of tirasemtiv, a fast skeletal muscle troponin activator, as a potential treatment for patients with ALS J Shefner (USA)
16.40 – 16.55 Efficacy, safety and tolerability study of 1mg rasagiline in ALS: A prospective, randomized, parallel-group, double-blind trial A Ludolph (Germany)
16.55 – 17.10 Ibudilast: Bi-modal therapy with riluzole in early and advanced ALS patients B Brooks (USA)
17.10 – 17.25 Towards more efficient clinical trial designs in ALS: Lessons from the Edaravone Development Programme J Palumbo (USA)
17.25 - 17.45 Discussion

Day 1 Programme

Day One

Friday, 8 December

Day 2 Programme

Day Two

Saturday, 9 December

Day 3 Programme

Day Three

Sunday, 10 December